Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)
Update: 2025-09-22
Description
Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics:
- Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00 )
- Case: A woman in her early 40s with no actionable mutations (7:29 )
- Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13 )
- TROP2-directed ADCs (15:22 )
- Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21 )
- Novel strategies utilizing approved and investigational ADCs (23:28 )
- Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39 )
- ADCs in combination with immunotherapy (32:51 )
Comments
In Channel